Ignite Creation Date:
2024-05-06 @ 7:06 PM
Last Modification Date:
2024-10-26 @ 3:00 PM
Study NCT ID:
NCT05891795
Status:
RECRUITING
Last Update Posted:
2024-05-16
First Post:
2023-05-18
Brief Title:
Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy
Sponsor:
Stanford University
Organization:
Stanford University
Study Overview
Official Title:
Topical Androgen Receptor Inhibitor for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Mechanism-based acne treatment for transgender patients receiving testosterone currently does not exist and is an unmet medical need This study explores clascoterone to treat testosterone induced acne Many treatments we use to treat acne in females cannot be used in transgender males because they interfere with hormone therapy Androgens have been associated with the development of acne vulgaris Recently a topical androgen receptor inhibitor cream clascoterone has been FDA-approved for the treatment of acne However clinical trials of clascoterone have excluded participants on exogenous hormones Clascoterone has been hypothesized to be effective in the treatment of acne in transgender male participants on masculinizing hormone therapy but it has never been studied or reported in the literature
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None